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Abstract 
 
To identify genetic variants associated with diabetic retinopathy (DR), we performed a large, 
multiethnic genome-wide association study (GWAS). Discovery included eight European cohorts 
(n = 3,246) and seven African American cohorts (n = 2,611). We meta-analyzed across cohorts 
using inverse-variance weighting, with and without liability threshold modeling of glycemic 
control and duration of diabetes. Variants with a P value < 1 X 10-5 were investigated in replication 
cohorts that included 18,545 Europeans, 16,453 Asians and 2,710 Hispanics.  After correction for 
multiple testing, the C allele of rs142293996 in an intron of nuclear VCP-like (NVL) was associated 
with DR in European discovery cohorts (P = 2.1 x 10-9), but did not reach genome-wide 
significance after meta-analysis with replication cohorts. We applied the Disease Association 
Protein-Protein Link Evaluator (DAPPLE) to our discovery results to test for evidence of risk 
being spread across underlying molecular pathways. One protein-protein interaction network built 
from genes in regions associated with proliferative DR (PDR) was found to have significant 
connectivity (P=0.0009) and corroborated with gene set enrichment analyses.  These findings 
suggest that genetic variation in NVL, as well as variation within a protein-protein interaction 
network that includes genes implicated in inflammation, may influence risk for DR. 
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Diabetic retinopathy (DR) is a leading cause of blindness.(1) Established risk factors include 
longer duration of diabetes (DoD) and poor glycemic control.(2)  Genetic factors are also 
implicated, with heritability of 52% for proliferative diabetic retinopathy (PDR).(3, 4)  Several 
candidate gene and genome-wide association studies (GWAS) have been conducted.(5-11) While 
several polymorphisms have been suggested to be associated with DR, few have been convincingly 
replicated.(10, 12-15) 
 
There are several reasons why studies have not yielded consistent findings.  The genetic effects 
are likely modest and identification requires large sample sizes. Previous studies have not 
consistently accounted for the strongest two covariates, DoD and glycemic control. Liability 
threshold (LT) modeling is one way to incorporate these covariates while also increasing statistical 
power.(16)  Finally, previous genetic studies have largely examined individual variants.  
Techniques that examine top GWAS findings collectively for variants that cluster in biological 
networks based on known protein-protein interactions have the potential to identify variants where 
there is insufficient power to detect their individual effects. 
 
The purpose of this study was to identify genetic variants associated with DR by (1) assembling a 
large sample size through inclusion of multiple ethnicities, (2) incorporating DoD and glycemic 
control via LT modeling and (3) collectively examining variants that cluster in biological 
networks. 
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Research Design and Methods 
 
All studies conformed to the Declaration of Helsinki tenets and were Health Insurance Portability 
and Accountability Act (HIPAA) compliant. Written informed consent was obtained from all 
participants.  Institutional Review Board /Ethics Committee approval was obtained by each 
individual study.  
 
Discovery Sample Description 
The discovery sample, encompassing seven African American and eight European cohorts, arose 
from a consortium of 11 DR studies for a total of 3246 Europeans and 2611 African Americans. 
(6-8, 12, 13, 17, 18)  Inclusion criteria for the discovery stage were (1) type 2 diabetes and (2) 
European or African American ethnicity. Type 2 diabetes was defined as a fasting plasma glucose 
(FPG)  ≥ 126 mg/dL (7.0 mmol/L) or a hemoglobin A1C (HbA1C) ≥ 6.5% (48 mmol/mol) (19) with 
onset of the diabetes after age 30 years.  Table 1 summarizes the DR phenotyping protocols and 
covariates by discovery cohort. Phenotyping protocols have been previously described (4, 20-29) 
and additional details are in the Supplemental Materials.  
 
DR Case-Control Definitions 
The analysis plan pre-specified four DR case-control definitions with varying Early Treatment 
Diabetic Retinopathy Study (ETDRS) score thresholds for cases and controls (Table 2).(30)  The 
primary case-control definition compared any DR to no DR (ETDRS ≥ 14 vs. ETDRS < 14, 
henceforth referred to as the any DR analysis).  There were three secondary case-control 
definitions.  The first compared patients with PDR to those without PDR (ETDRS ≥ 60 vs. ETDRS 
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< 60, henceforth the PDR analysis).  The second compared those with non-proliferative DR 
(NPDR) or worse to those without DR (ETDRS ≥ 30 vs. ETDRS < 14, henceforth the NPDR 
analysis).  The third compared those with PDR to those without DR (ETDRS ≥ 60 vs. ETDRS < 
14, henceforth the extremes of DR analysis).  The rationale for four definitions is in the 
Supplemental Materials.  Table 1 shows the available samples by cohort and ETDRS score 
thresholds. Supplemental Table 1 summarizes the mean values for glycemic control and DoD. 
 
Statistical Analyses 
The genotyping platforms and the numbers of single nucleotide polymorphisms (SNPs) genotyped 
are summarized in Supplemental Table 2. Details about quality control, imputation, and data 
filtering are in the Supplemental Materials. Supplemental Figure 1 provides a flow chart of the 
discovery and replication analyses.  For the four main case-control definition analyses, we 
performed each of the analyses (1) without incorporating DoD and glycemic control using 
EIGENSOFT (16, 31) and (2) with LT modeling of DoD and glycemic control using 
LTSCORE.(16)   LT modeling details are in the Supplemental Materials.  Both the EIGENSOFT 
and LTSCORE tests were implemented in LTSOFT version 2.0 (see Web Resources in 
Supplemental Material). For the discovery analyses, we ran principal components (PC) analysis 
with EIGENSTRAT using only typed SNPs and five PCs, separately by ethnicity and case-control 
definition.(32)  We computed association analyses for each of the seven African American and 
eight European cohorts separately and then meta-analyzed by ethnicity. Meta-analysis was 
performed using inverse-variance weighting, accounting for both effective sample size (defined as 
4/[1/Ncase + 1/Ncontrol]) and allele frequency.(33)  We also performed multiethnic (Europeans and 
African Americans together) meta-analyses for the any DR and PDR analyses using inverse-
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variance weighting and a sensitivity analysis of the any DR meta-analyses in African Americans 
and Europeans (see Supplemental Materials). Because we included rare variants in this GWAS, 
we also tested the robustness of the top associations (P < 5 × 10–8) by performing two additional 
tests: (1) a Fisher’s exact test on cases or controls aggregated across all cohorts tested per variant 
and on each cohort separately and (2) an inverse variance-weighted meta-analysis across cohorts 
using the natural logarithm of the odds ratio as the effect size (34) without adjusting for covariates. 
 
P-value thresholds for genome-wide significance 
The P-value thresholds for genome-wide significance were based on empirically-determined 
thresholds for different ancestral populations that account for the GWAS multiple testing burden, 
as well as population-specific linkage disequilibrium (LD) patterns (35): 
 
(1) P < 3.24 X 10-8 for SNPs ascertained in African ancestry populations 
(2) P < 5.0 X 10-8 for SNPs ascertained in European ancestry populations 
(3) P < 3.24 X 10-8 for SNPs ascertained in multiethnic meta-analyses   
 
We further corrected these thresholds for additional multiple testing from examination of four 
case-control definitions, each with and without covariate incorporation, for eight tests total.  This 
yielded the following P-value thresholds for our study: 
 
(4) P < 3.75 X 10-9 for SNPs ascertained in African ancestry populations  
(5) P < 6.25 X 10-9 for SNPs ascertained in European ancestry populations 
(6) P < 3.75 X 10-9 for SNPs ascertained in multiethnic meta-analyses 
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We note that correction for eight tests is conservative, because the case-control definitions are not 
completely independent.  We did not apply further multiple testing correction for the different 
ancestries analyzed.  
 
Replication Meta-Analysis 
Eight European, eight Asian and four Hispanic replications cohorts provided summary statistics 
on SNPs with P < 1 X 10-5 in the discovery analyses (Table 3). Their phenotyping/genotyping 
protocols have been previously described and details are in the Supplemental Material. (6-8, 12, 
13, 17, 18)  The rationale for including additional ethnicities in the replication phase is that high 
trans-ethnic genetic correlations have been documented for type 2 diabetes and other traits/diseases 
and support the use of multiethnic studies to increase sample size.(36) Supplemental Table 3 
summarizes the replication cohorts’ mean values for HbA1C, FPG, and DoD. Replication was in 
silico with existing genotyping. LT modeling was not applied to the replication cohort analyses.  
The replication cohorts used standard covariate adjustment in their regression models. Replication 
meta-analysis was also performed using inverse-variance weighting – first individually by each 
ethnicity (Europeans, Hispanics, Asians) followed by all cohorts combined.  Replicated genome-
wide significance had to meet the aforementioned thresholds after meta-analysis of the discovery 
and replication results.   
 
 
 
Protein-Protein Interaction Analysis of Top GWAS Loci 
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To identify significantly-enriched protein networks among the loci with the highest statistical 
evidence for association to DR, we applied the Disease Association Protein-Protein Link Evaluator 
(DAPPLE) to our discovery GWAS.(37) It has been shown that top associated loci, despite not 
being genome-wide significant, tend to cluster in biological networks.(37, 38) For this reason, we 
examined the top 1000 loci from the discovery GWAS in the two mono-ethnic analyses (European 
and African American) and for each of the four case-control definitions analyses which 
incorporated DoD and glycemic control (eight network analyses in total). Our threshold for 
significance was therefore P < 0.00625 (0.05 corrected for eight tests). We used the publically 
available version of DAPPLE, and the protocol is outlined in the Supplemental Materials. This 
methodology has been used successfully with previous GWAS to identify protein networks with 
biological relevance.(37-39) 
 
Gene Set Enrichment Analysis of DAPPLE significant genes 
To further support the protein-protein interaction results from the DAPPLE analysis, we applied 
gene set enrichment analysis (GSEA) using MAGENTA (Meta-Analysis Gene-Set Enrichment of 
variaNT Associations) (40) to the set of genes significantly enriched for protein-protein 
interactions in the DAPPLE analysis (details in Supplemental Materials).   
 
Type 2 diabetes and Associated Glycemic Traits Loci 
To understand to what extent genetic determination of DR might reflect enrichment for type 2 
diabetes or glycemic control genes, we computed a correlation between case status in the any DR 
analysis and the sum of the beta*risk allele (for quantitative glycemic traits) or logOR*risk allele 
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(for type 2 diabetes) of the trait-associated SNPs for each cohort and each trait (see Supplemental 
Materials for details).  
 
Results 
 
Discovery Meta-Analysis 
Supplemental Figure 2 shows the PC analysis. We observed little inflation in the association 
statistic distribution (Supplemental Figure 3), indicating no significant population stratification as 
a confounder. Supplemental Figure 4 shows the Manhattan plots for the any DR analyses. 
Supplemental Tables 4 - 25 show the top 10 SNPs for independent loci with the lowest P values 
for each discovery analysis, including the sensitivity analyses (full results available at 
https://www.ncbi.nlm.nih.gov/gap).   
 
Table 4 shows SNPs that met the traditional nominal threshold for genome wide significance of P 
< 5 X 10–8 from the discovery analyses. All of the SNPs in Table 4 were either from the PDR or 
extremes of DR analyses; Figure 1 shows the QQ and Manhattan plots for the PDR and extremes 
of DR analyses. The results for the associations in Table 4 are shown for each cohort separately in 
Supplemental Table 26. Results for these SNPs after meta-analysis with replication samples both 
combined and separated by ethnicity are shown in Table 5 and Supplemental Table 27, 
respectively.   
 
Genome-Wide Significant Finding from the Discovery Analyses in NVL Gene 
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Using the corrected significance thresholds, only one SNP in the discovery meta-analyses met 
genome-wide significance: rs142293996 for the extremes of DR analysis incorporating DoD and 
glycemic control in Europeans (P = 2.1 X 10-9). The association was not significant without 
adjusting for covariates based on a Fisher’s exact test (Supplemental Table 28). This is an intronic 
variant in the  nuclear VCP-like (NVL) gene which encodes a member of the AAA (ATPases 
associated with diverse cellular activities) superfamily.(41)  The NVL gene is widely expressed in 
vivo with highest expression in retina (https://www.proteinatlas.org/ENSG00000143748- 
NVL/tissue#top).  
 
We tested whether this association was a significant cis-expression quantitative trait locus (eQTL) 
in the Genotype-Tissue Expression (GTEx) Project release v7 (see Supplemental Materials for 
eQTL analysis details). This variant, rs142293996, lies in the 22nd intron of NVL and is in LD 
(r2=0.62) with variant rs41271487 in the 24th intron of NVL. Rs41271487 is a significant eQTL (P 
= 6.4 X 10-6, effect size=1.27) in the GTEx spinal cord cervical c-1 tissue, targeting calpain 2 
(CAPN2), a calcium-activated neutral protease (Supplemental Figure 5). Common variants in the 
intron or regulatory region of CAPN2, 527-576 kb upstream of the DR association, are associated 
with variation in serum alpha-carotene levels (42), a vitamin A precursor required for sight, 
supporting a functional role for this gene. Based on the eQTL analysis, increased expression of 
CAPN2 is associated with decreased risk of DR (Supplemental Figure 6).  CAPN2 is expressed in 
the retina (https://www.proteinatlas.org/ENSG00000162909-CAPN2/tissue).    
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When examined in the replication analyses (which included a more diverse population), the 
direction of effect in the replication cohorts for rs142293996 was the same but the meta-analysis 
P-value was not genome-wide significant (P = 4.10 X 10-6).   
 
 
Top Finding from the African American Discovery Analyses 
In African Americans, the SNP with the lowest P value was rs115523882 from the PDR analysis 
(P = 5.37 X 10-9). This was short of the 3.75 x 10-9 threshold for significance in African Americans.  
We could not reproduce this finding in the replication cohorts. This variant is located near the 
GOLIM4 gene, which helps process proteins and mediates protein transport. The SNP 
rs115523882 specifically changes a motif which is a binding site for Nlx3, a transcription factor 
in blood, suggesting it plays a regulatory role. This variant is mainly present in people of African 
ancestry [minor allele frequency (MAF) = 0.0393] and not common in other ethnic groups, 
suggesting we may have had insufficient power to replicate it. 
 
Of note, there was one SNP, rs184340784, suggestively associated with DR (P = 3.52 X 10-8) in 
the extremes of DR analysis without covariates in African Americans that was not present in our 
replication cohorts (due to low MAF) and thus could not be replicated. Neither rs115523882 nor 
rs184340784 were analyzed for eQTL activity in GTEx due to their low MAF (MAF<0.01 in 
GTEx tissues). 
 
Table 6 and Supplemental Table 29 show the discovery variants with P < 1 X 10-5 that achieved a 
nominal P < 0.05 in the complete replication sample or in one of the replication ethnicities, 
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respectively, and had the same direction as the discovery samples.  None of these variants achieved 
genome-wide significance after discovery and replication meta-analysis, as defined above. 
 
DAPPLE Results Protein-Protein Interactions 
One protein network from the African American PDR analysis was significant (P=0.0009) for 
average binding degree within the network (Figure 2). The aforementioned top ranked SNP 
(rs115523882) could not be included in the DAPPLE analysis since its nearby gene (GOLIM4) is 
not in the protein database. The significant protein network includes genes with primary roles in 
inflammation including IFNG, IL22RA1, CFH and SELL. INFG encodes INF-γ which is highly 
expressed in ocular tissues from PDR patients.(43) IL22RA1 encodes the IL-22 receptor and CFH 
encodes complement factor H; both proteins are suspected to play a role in PDR.(44, 45) SELL 
encodes L-selectin, which is expressed at higher levels in lymphocytes from DR patients and 
associated with increased endothelial adhesion.(46) We did not identify any statistically significant 
protein networks for any of the other case-control definitions in African Americans or in 
Europeans. 
 
MAGENTA Confirmation of DAPPLE Results 
We examined the 41 genes in the significant network identified by the DAPPLE analysis via GSEA 
using MAGENTA.  The genes showed a significant (16.5-fold) enrichment of low association P-
values in the African American PDR analysis (P < 1 X 10-6; Supplemental Figure 7 and 
Supplemental Table 30) and to a lesser extent in African American extremes of DR analysis (P =2 
X 10-4; Supplemental Table 30), suggesting new DR associations of modest effects in African 
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Americans (Supplemental Table 31). No significant gene set enrichment was found for the PDR 
and extremes of DR analyses in Europeans. 
 
Loci Associated with Type 2 Diabetes and Glycemic Traits 
The results of the correlation analysis between type 2 diabetes/glycemic trait-associated SNPs and 
DR case status are shown in Supplemental Table 32.  The Z-score for type 2 diabetes was +2.256 
(P=0.024).  The correlation coefficient R was positive, indicating that a greater burden of SNPs 
that increase type 2 diabetes risk is correlated with having DR.  However, this Z-score was not 
significant after correcting for the six hypotheses (six traits) tested.   
 
Previously associated SNPs from Prior Studies 
We extracted results from our discovery meta-analysis for the variants with the lowest association 
P-values from previously published DR GWAS or large candidate gene studies (Supplemental 
Table 33).  There were three variants that were nominally significant (P < 0.05) in our sample and 
had the same direction of effect as the previously published studies. Two of the variants—
rs9896052 and rs6128—were from previous studies whose samples overlapped with some samples 
in our discovery meta-analysis, and therefore do not represent independent replication.(10, 20) 
Variant rs1399634, originally found in Chinese patients (P = 2 x 10-6), was nominally significant 
in our European discovery cohort (P = 0.0124). Meta-analysis of the original study and our cohorts 
was performed using the same method as our discovery and replication meta-analyses and was 
short of genome-wide significance (OR = 1.47, P = 9.63 X 10-8). 
 
Discussion 
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To our knowledge, this study represents the largest GWAS performed for DR. The discovery 
analysis included 3,246 Europeans and 2,611 African Americans. The replication analysis 
included 18,545 Europeans, 16,453 Asians, and 2,710 Hispanics.  Despite the relatively large 
sample size, we did not identify any individual variants that were associated at a genome-wide 
significant level after meta-analysis with multiethnic replication cohorts. However, among the 
most significant results in the African American PDR analysis, we did identify a statistically 
significant enrichment for a network of genes using DAPPLE which was corroborated by GSEA 
using MAGENTA.   
 
In the discovery meta-analyses, several variants from the PDR and extremes of DR analyses 
achieved nominal genome-wide significance of P < 5 X 10-8, but the only variant to achieve 
genome-wide significance after conservative multiple testing correction was rs142293996 in the 
European analysis for extremes of DR (P = 2.1 X 10-9).  It is notable that the variants with the most 
significant findings came from the two case-control definitions that have PDR as their case 
definition.  This is consistent with the fact that PDR has a higher heritability than overall DR.(4)  
While the most strongly associated variants in the discovery analyses (rs142293996 in NVL in 
Europeans and rs115523882 in GOLIM4 in African Americans) did not reach genome-wide 
significance with replication, it is still possible that they do play a role in DR pathogenesis.  NVL 
is highly expressed in the retina and the implicated variant is in LD with an eQTL acting on CAPN2 
with functional implications in neural tissue.  The eQTL variant falls in a binding site of a 
transcription factor.(47)   The GOLIM4 variant also has a known regulatory role.  
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We could not replicate the association with rs142293996 when we used the Fisher’s exact test, 
although the Fisher’s exact test did not allow for covariate incorporation.  There is potential for 
inflated false positive rate when standard association methods are applied to rare (e.g. MAF < 1%) 
variants in imbalanced (e.g. case fraction < 10%) case-control cohorts at modest sample 
sizes.(48)  However, most cohorts in this study did not have case fraction <10%. Larger sample 
sizes will help determine the confidence in these top associations. 
 
There was one variant suggestively associated in the extremes of DR discovery analysis in African 
Americans, rs184340784, which was not present in any replication datasets.  The T allele of this 
variant has a frequency of 0.0023 in African populations and 0 in European, East Asian, South 
Asian and Hispanic populations in the 1000 Genomes Phase 3 panel.  In the discovery analysis, 
the P = 3.52 X 10-8 was shy of the genome-wide significance threshold of 3.75 X 10-9 for variants 
discovered from the African ancestry analyses.  This variant is within an intronic region upstream 
of adherens junctions associated protein 1 (AJAP1) which has its highest expression in brain frontal 
cortex but is also expressed in the retina (https://www.proteinatlas.org/ENSG00000196581-
AJAP1/tissue). 
 
In the DAPPLE analysis, we did find that the top signals for the PDR analyses in African 
Americans analysis were enriched for a biologic network. The advantage of DAPPLE is that it can 
identify a protein pathway which may not be evident solely from the primary individual variant 
GWAS.  The presence of an underlying network amongst the top loci suggests there are likely true 
associations within top findings that have yet to reach genome-wide significance due to limited 
power.  Multiple pathways including inflammatory pathways are implicated by this network. To 
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confirm biological significance, these results will need to be followed up with functional in vitro 
studies. 
 
The DAPPLE results were corroborated by the MAGENTA GSEA in the African American PDR 
and extremes of DR analyses. This network of genes, however, was not enriched for in Europeans. 
This could either be due to technical differences, e.g., the number of African American cases is 
~3-fold larger than the number of European cases, or to biological reasons. For example, we found 
that the allele frequencies of the most significant variant per gene for 40% of these protein 
interacting genes are rare in Europeans (MAF < 0.2%), while common in African Americans 
(MAF > 1%), according to the Genome Aggregation Database (gnomAD, see Web Resources). 
 
In the analysis between type 2 diabetes/glycemic trait SNPs and DR case status, only type 2 
diabetes variants were significantly associated with DR prior to, but not after, multiple testing 
correction.  One previous study examined aggregate effects of 76 type 2 diabetes-associated 
variants in Asian patients.(49) Participants in the top tertile of type 2 diabetes-risk score were 2.56-
fold more likely to have DR compared with lowest tertile participants.  Our study’s result showed 
the same direction of effect as the prior study, with type 2 diabetes risk raising alleles increasing 
DR risk. The prior study did not examine glycemic traits.  Our inability to detect a correlation for 
glycemic traits may be due to the small amount of glycemic variance captured by these variants. 
In European patients, HbA1C SNPs explain approximately 5% of HbA1C variance.(50)    
We were unable to replicate findings from previous studies.(6-8, 12, 13, 17, 18) We did have the 
same direction of effect in our European discovery sample for rs1399634 (LRP2) which was 
initially reported in an Asian population.  However, the meta-analysis was shy of genome-wide 
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significance. The overall lack of replication of previous reports’ findings is not surprising, given 
the heterogeneity in phenotyping, case-control definitions, ethnicities and analytic approaches, 
although we did try to match our case-control definitions to the original studies’ definitions. 
 
There are many potential reasons why we were unable to identify replicable, significant 
associations from our discovery GWAS.  First, the genetic risk in DR development may be quite 
small in proportion to the non-genetic risk factors.  Therefore, even though we assembled the 
largest sample, it may not be sufficient to detect very modest effects.  There was heterogeneity 
between the discovery and replication cohorts that could contribute to inability to replicate.  The 
discovery cohort included individuals with type 2 diabetes while the replication cohorts included 
individuals with either type 1 or type 2 diabetes.  It is not known definitively whether genetic 
variants for DR differ between type 1 and type 2 diabetes. Clinically, DR phenotypes are similar 
in patients with type 1 and type 2 diabetes, so we hypothesize that at least some of the genetic risk 
is shared. However, we cannot be certain of this and heterogeneity of diabetes type might have 
contributed to lack of replication. The discovery cohort included individuals who were of either 
European or African American descent while the replication cohorts included individuals of 
European, Hispanic, or Asian descent. This heterogeneity could also have led to lack of replication. 
Europeans were represented in both the discovery and replication phases, but even our European 
discovery analysis has limited power. Power calculations show that our discovery GWAS for the 
any DR analysis in Europeans had 100% power to detect a variant with a MAF of 0.40 with a 
heterozygous genotypic relative risk (GRR) of 1.5 with a P-value < 5 X 10-8, whereas the power 
decreases to 5% for the same variant with GRR of 1.2.  
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We attempted to harmonize the phenotypes as much as possible, but there were some limits to 
complete harmonization, particularly for cohorts with limited-field or no photography.  
Misclassification of participants because of limited DR ascertainment could have biased the results 
to the null.  Although we did use LTSCORE modeling to account for DoD, we may have had some 
misclassification bias because we did not have a minimum DoD for controls – i.e. some controls 
could have developed DR with longer DoD - which would also bias our result towards the null.  
We only had one HbA1c measure. Repeated HbA1c measures would reflect long-term glycemia 
more accurately.   
 
In summary, we have executed the largest GWAS of DR to date.  There were no genome-wide 
significant findings but analysis of protein-protein interaction networks point to possible candidate 
pathways for PDR in African Americans.  Future studies examining DR genetics would benefit 
from a greater international collaboration encompassing larger samples that would allow strict 
case-control definitions that define a minimal DoD without sacrificing power.  Furthermore, these 
studies should focus case definitions on the advanced forms of DR—PDR and diabetic macular 
edema (DME)—and incorporate more refined phenotyping, particularly optical coherence 
tomography for DME. Finally, whole genome sequencing might reveal a role for very rare variants, 
particularly for the DR phenotypic extremes. 
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Table 1.  Studies included in the discovery sample 
Study Population 
Diabetes 
Type 
# of Eyes/ 
# of Fields/ 
Size of Fields 
Photographed 
 
Diabetes 
Duration 
Glycemic 
Control 
Measure 
Cases 
(ETDRS ≥ 
14) 
Ctrls 
(ETDRS < 
14) 
Cases 
(ETDRS ≥ 
60) 
Ctrls 
(ETDRS < 
60) 
Cases 
(ETDRS ≥ 
30) 
AAPDR AA 2 2/7/30 deg.  Y HbA1C 274 56 255 75 261 
AGES* EUR 2 2/2/45 deg.  Y HbA1C 85 222 3 304 8 
ARIC AA 2 1/1/45 deg.  Y HbA1C 96 265 3 358 73 
 EUR 2 1/1/45 deg.  Y HbA1C 126 632 6 752 80 
AUST EUR 2 NA‡  Y HbA1C 522 435 187 770 346 
BMES EUR 2 2/5/30 deg.  Y FPG 124 208 1 331 37 
CHS AA 2 1/1/45 deg.  Y FPG 19 35 4 50 14 
 EUR 2 1/1/45 deg.  Y FPG 26 119 4 141 16 
FIND-Eye* AA 2 2/2/45 deg.†  Y HbA1C 330 167 264 233 303 
 EUR 2 2/2/45 deg.†  Y HbA1C 158 154 115 197 145 
JHS AA 2 2/7/30 deg.  Y HbA1C 91 160 12 239 57 
MESA AA 2 2/2/45 deg.  Y HbA1C 101 258 11 348 60 
 EUR 2 2/2/45 deg.  Y HbA1C 38 200 2 236 12 
RISE/RIDE EUR 2 2/7/30 deg.  Y HbA1C -- -- 80 117 -- 
WFU AA 2 NA‡  Y HbA1C -- -- 548 211 -- 
TOTAL AA 2 --  Y Varies 911 941 1097 1514 768 
TOTAL EUR 2 --  Y Varies 1079 1970 398 2848 644 
Ctrls= Controls, AAPDR = African American Proliferative Diabetic Retinopathy Study, AGES = Age, Gene/Environment 
Susceptibility Study, ARIC = Atherosclerosis Risk In Communities Study, AUST= Australian Genetics of Diabetic Retinopathy 
Study, BMES = Blue Mountains Eye Study, CHS=Cardiovascular Health Study, FIND-Eye = Family Study of Nephropathy and 
Diabetes-Eye, JHS = Jackson Heart Study, MESA = Multiethnic Study of Atherosclerosis, RIDE/RISE= Ranibizumab Injection in 
Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes, WFU=Wake Forest University, 
AA=African American, EUR = European, Illum=Illumina, Affy=Affymetrix, NA=not available, Y=information on diabetes duration 
is available, HbA1C=hemoglobin A1C, FPG=fasting plasma glucose, deg.= degrees, SNPs= single nucleotide polymorphisms, 
QC=quality control 
* Cohorts without access to raw genotype information 
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† Not all FIND-Eye subjects had photographs but all participants had harmonization of exam and clinical data to an ETDRS score. 
‡ The AUST study used examination by an ophthalmologist to ascertain diabetic retinopathy.  The WFU study used a questionnaire to 
ascertain diabetic retinopathy. 
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Table 2.  Four case-control definitions and the number of samples available for discovery for each definition. 
 
 Controls  Cases 
Analysis Name Score n AA n EUR  Score n AA n EUR 
Any DR (Primary Analysis) < 14 941 1970  ≥ 14 911 1079 
PDR < 60 1514 2848  ≥ 60 1097 398 
NPDR < 14 941 1970  ≥ 30 768 644 
Extremes of DR < 14 941 1970  ≥ 60 1097 398 
DR= diabetic retinopathy, PDR = proliferative diabetic retinopathy, NPDR = non-proliferative diabetic retinopathy, Score = ETDRS 
score range, AA = African American, EUR= European  
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Table 3. Studies included in the replication meta-analyses 
 
Cohort by Ancestry Ethnicity/ 
Nationality 
DM 
Type 
Any DR 
Analysis 
PDR Analysis NPDR Analysis Extremes of DR 
Analysis 
   Cases Controls Cases Controls Cases Controls Case Controls 
Asian 
KSDR Korean 2 1516 571 918 1167 1300 571 918 571 
MESA  Chinese 2 28 83 -- -- 17 83 -- -- 
RIKEN Japanese 2 5532 5565 -- -- 2371 5565 -- -- 
SCES I Chinese 2 75  228  -- -- -- -- -- -- 
SCES II Chinese 2 27  78  -- -- -- -- -- -- 
SiMES Malay 2 214  557  -- -- -- -- -- -- 
SINDI Indian 2 315 669  -- -- -- -- -- -- 
TUDR Chinese 2 -- -- -- -- -- -- 436  559 
European 
DCCT/EDIC  
Primary cohort 
North 
American 
1 -- -- 53  598  -- -- -- -- 
DCCT/EDIC 
Secondary cohort, 
conventional treatment 
North 
American 
1 -- -- 114  209 -- -- -- -- 
DCCT/EDIC 
Secondary cohort, intensive 
treatment 
North 
American 
1 -- -- 42 288  -- -- -- -- 
GENESIS/GENEDIAB French 1 277  999  808  468  277 607  277  468 
GoDARTS Scottish  2506  2412 574 4345 1381 2412 574 2412 
GoKinD North 
American 
1 -- -- 138 581 -- -- -- -- 
SUMMIT European 1 and 
2 
5422 4302 -- -- -- -- -- -- 
WESDR North 
American 
1 -- -- 309 294 -- -- -- -- 
Hispanic 
GOLDR Hispanics 2 298  301 76 523 215 301 76 301 
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LALES Hispanics 2 552 500 53 999 341 500 53 500 
MESA Hispanics 2 92 192 -- -- 52 192 -- -- 
SCHS Mexican 
Americans 
2 528 247 103 672 406 247 103 247 
Total   17382 16704 3188 10144 6360 10478 2437 5058 
DM = diabetes mellitus, KSDR = Korean Study of Diabetic Retinopathy, MESA = Multiethnic Study of Atherosclerosis, RIKEN  = 
Rikagaku Kenkyusho - Institute of Physical and Chemical Research, SCES= Singapore Chinese Eye Study, SiMES = Singapore 
Malay Eye Study, SINDI = Singapore Indian Eye Study, DCCT/EDIC = Diabetes Control and Complications Trial/Epidemiology of 
Diabetes Interventions and Complications, GENESIS/GENEDIAB=Genetics nephropathy and sib pair study/Genetics, nephropathy, 
diabetes, GoDARTS =Genetics of Diabetes and Audit Research Tayside Study, GoKinD = Genetics of Kidneys in Diabetes, 
SUMMIT = Surrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools, WESDR = Wisconsin 
Epidemiologic Study of Diabetic Retinopathy, GOLDR = Genetics of Latino Diabetic Retinopathy, LALES = Los Angeles Latino Eye 
Study, SCHS = Starr County Health Studies, TUDR = Taiwan–US Diabetic Retinopathy Study 
 
The SUMMIT cohort is a meta-analysis of three European studies: The Finnish Diabetic Nephropathy (FinnDiane) Study; Scania 
Diabetes Registry; and the Eurodiab study. 
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Table 4. Variants with P < 5 x 10-8 (traditional, nominal threshold for genome wide significance) in the discovery analyses  
 
       CASES CONTROLS    
 
Case Control 
Definition 
Population/ 
LT Modeling 
RSID CHR Position Nearest Gene REF N RAF N RAF NEFF P OR 95% CI 
 
PDR AA/no rs115523882 3 167876205 GOLIM4 A 1105 
0.982
3 
1119 0.9611 1452 9.42 X 10-9 
3.1
0 
2.12, 4.53 
PDR AA/yes rs115523882 3 167876205 GOLIM4 A 1105 
0.982
3 
1119 0.9611 1452 5.37 X 10-9 
3.1
0 
2.14, 4.50 
PDR EUR/no rs139205645 2 201949806 NDUFB3 T 309 
0.972
5 
975 0.9959 907 3.93 X 10-8 
0.1
3 
0.06, 0.27 
PDR EUR/yes rs17791488 17 26232732 NOS2/LYRM9 T 309 
0.987
1 
975 0.9661 907 7.26 X 10-9 
3.7
0 
2.40, 5.71 
Extremes of DR AA/no rs184340784 1 4589883 AJAP1 C 520 0.999 230 0.9784 603 3.52 X 10-8 NA NA 
Extremes of DR EUR/yes rs142293996 1 224448059 NVL C 187 
0.994
7 
435 0.9874 523 2.10 X 10-9 
2.3
8 
1.80, 3.14 
Extremes of DR EUR/yes rs17706958 3 73837141 PDZRN3 T 308 
0.813
9 
594 0.7332 797 3.04 X 10-8 
1.5
8 
1.35, 1.85 
Extremes of DR EUR/yes rs80117617 2 40855125 SLC8A1 T 308 
0.983
8 
594 0.9445 797 4.04 X 10-8 
3.7
8 
2.37, 6.02 
 
LT= liability threshold, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, RAF= 
reference allele frequency, OR= odds ratio for reference allele, CI = confidence interval, AA= African Americans, EUR = European 
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Table 5. Replication results for variants with P < 5 x 10-8 (traditional, nominal threshold for genome wide significance) in the 
discovery analysis  
 
Discovery 
Population/ 
LT modeling 
RSID Nearest Gene REF 
Disc 
NEFF 
Disc 
RAF 
Disc P 
Disc 
OR 
All 
Rep 
NEFF 
All 
Rep 
RAF 
All 
Rep 
OR 
All 
Rep 
P 
Disc + REP OR 
(95% CI) 
Disc + Rep 
P 
Variants identified in the PDR Discovery Analysis 
AA/no rs115523882 GOLIM4 A 1452 0.9721 9.42 X 10-9 3.10 571 0.9975 0.20 0.13 2.89 (1.97, 4.23) 8.51 X 10-8 
AA/yes rs115523882 GOLIM4 A 1452 0.9721 5.37 X 10-9 3.10 571 0.9975 0.20 0.18 2.89 (1.99, 4.20) 4.25 X 10-8 
European/no rs139205645 NDUFB3 T 907 0.9907 3.93 X 10-8 0.13 3431 0.9900 0.74 0.77 0.48 (0.29, 0.79) 0.004 
European/yes rs17791488 NOS2/LYRM9 T 907 0.9705 7.26 X 10-9 3.70 5883 0.9772 0.82 0.33 1.08 (0.98, 1.19) 0.12 
Variants identified in the Extremes of DR Analysis 
AA/no rs184340784 AJAP1 C 603 0.0063 3.52 X 10-8 NA * * * * -- -- 
European/yes rs142293996 NVL C 523 0.9895 2.10 X 10-9 2.38 1229 0.9910 3.23 0.16 2.91 (1.85, 4.57) 4.10 x 10-6 
European/yes rs17706958 PDZRN3 T 797 0.7615 3.04 X 10-8 1.58 4194 0.9828 1.28 0.02 1.39 (1.24, 1.56) 7.41 x 10-8 
European/yes rs80117617 SLC8A1 T 797 0.9598 4.04 X 10-8 3.78 3345 0.9726 1.29 0.24 1.71 (1.30, 2.25) 1.35 x 10-4 
 
LT= liability threshold, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, RAF= 
reference allele frequency in sample, ALL= all replication cohorts, OR= odds ratio for reference allele, CI = confidence interval, PDR 
= proliferative diabetic retinopathy, DR = diabetic retinopathy, AA= African Americans 
* None of the replication cohorts were able to provide data for this SNP. 
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Table 6. Replication results for variants with nominal significance (P <0.05) in the combined (Hispanic, African American, and 
European cohorts) replication meta-analyses 
Discovery Population/ 
LT modeling 
RSID Nearest Gene REF* 
DISC 
EAF 
DISC 
OR 
DISC P 
ALL 
REP 
OR 
ALL 
REP P 
DISC + 
REP OR 
 
DISC + 
REP P 
 
Variants identified in the Any DR Discovery Analysis 
European (Sens)/no rs1394919 PPEF2/NAAA C 0.72 0.73 8.51 X 10-6 0.91 0.003 0.88 6.35 X 10-6 
AA (Sens)/no rs75360147 SLC28A3 T 0.93 2.08 7.07 X 10-6 2.65 0.009 2.17 2.29 X 10-7 
European/no rs1508244 HTR1E A 0.98 0.33 3.74 X 10-6 0.92 0.01 0.90 0.002 
ME/no rs10432638 UBXN2A C 0.73 0.78 2.60 X 10-6 0.93 0.01 0.89 7.74 X 10-6 
EU/no rs150775408 BC031225 C 0.95 1.97 7.24 X 10-6 1.27 0.04 1.46 2.54 X 10-5 
AA/yes rs143894698 GCM1 G 0.98 3.14 4.62 X 10-6 1.45 0.004 1.58 2.53 X 10-5 
European/yes rs13006587 ATAD2B G 0.58 0.79 7.52 X 10-6 0.93 0.006 0.92 4.74 X 10-5 
European/yes rs73642012 PTPRD C 0.91 0.67 9.58 X 10-6 0.90 0.02 0.87 8.67 X 10-5 
Variants identified in the PDR Discovery Analysis 
Europeans/no rs139921826 PRSS35 G 0.98 0.33 7.92 X 10-6 0.66 0.03 0.62 0.0008 
AA/yes rs1414474 C1orf94 C 0.14 1.62 1.46 X 10-7 1.12 0.01 1.19 1.90 X 10-5 
AA/yes rs9998354 BTF3P13 T 0.44 0.73 8.74 X 10-6 0.92 0.04 0.87 0.0001 
European/yes rs142293996 NVL C 0.99 1.83 1.14 X 10-6 2.40 0.04 2.29 0.0001 
Variants identified in the NPDR Discovery Analysis 
European/no rs1508244 RN7SL643P A 0.98 0.32 8.13 X 10-6 0.89 0.005 0.87 0.0005 
European/no rs7944308 KCNA4 G 0.42 0.71 7.76 X 10-7 0.94 0.02 0.90 5.80 X 10-5 
Variants identified in the Extremes of DR Discovery Analysis 
AA/no rs74161190 TCERG1L A 0.94 0.32 4.57 X 10-6 0.40 0.03 0.32 7.16 X 10-7 
European/yes rs17706958 PDZRN3 T 0.76 1.58 3.04 X 10-8 1.28 0.02 1.39 7.41 X 10-8 
European/yes rs10932347 CPS1 A 0.04 0.33 4.22 X 10-7 0.64 0.02 0.55 1.30 X 10-5 
AA/yes rs2690028 KAZN C 0.32 0.62 4.52 X 10-6 0.80 0.03 0.74 1.72 X 10-5 
European/yes rs116972715 DSC3 C 0.99 2.60 2.48 X 10-6 3.62 0.03 3.29 1.59 X 10-5 
European/yes rs75167957 CTNNA2 C 0.99 3.26 3.36 X 10-6 9.77 0.04 6.34 5.83 X 10-6 
AA/yes rs6577631 LOC339862 G 0.86 0.53 3.45 X 10-6 0.89 0.04 0.84 0.0006 
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Sens= Sensitivity Analysis, ME = Multiethnic, AA = African American, DR = diabetic retinopathy, PDR = proliferative diabetic 
retinopathy, NPDR = non-proliferative diabetic retinopathy. * For insertions-deletion, the reference allele is shown first followed by 
the alternate allele 
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Figure Legends 
Figure 1. Quantile-quantile and Manhattan plots for the PDR and extremes of DR discovery meta-analyses for: (A and B) PDR 
analysis in African American participants with liability threshold modeling of duration of diabetes and glycemic control; (C and D) 
PDR analysis in European participants with liability threshold modeling of duration of diabetes and glycemic control; (E and F) 
Extremes of DR analysis in African American participants with liability threshold modeling of duration of diabetes and glycemic 
control; and (G and H) Extremes of DR analysis in European participants with liability threshold modeling of duration of diabetes and 
glycemic control. The horizontal line in each of the Manhattan plots indicates the nominal threshold for genome-wide significance (P 
= 5 X 10-8). 
 
Figure 2. Protein network from the African American proliferative diabetic retinopathy discovery analysis that was significant in the 
DAPPLE analysis.  This significant protein network includes genes with primary roles in inflammation (IFNG, IL22RA1, CFH, SELL), 
protein function/endoplasmic reticulum function (ADAMT30, ERP44, HSP90B1, SPON1, CNAX, WFS1), catabolic 
processing/metabolism (PPT1, ALDH1B1), gene expression/transcription factor activity (HNRNPH1, TAF4, POLR2E, TCEB1, 
COMMD1, PLAGL1, THRB, SIN3A), macromolecule transport (NUP153, NUP50), protein localization (SEC61B, SEC61A2), and DNA 
repair/cell cycle (RBBP8, ATM, EEF1E1).  
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